Alnylam Pharmaceuticals, Inc. vs Kroger Co — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $220.35 (market cap $29.60B), while Kroger Co trades at $56.09 (market cap $34.46B). The key difference: Kroger Co is the larger of the two by market cap, and Kroger Co pays a 2.56% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | KR | |
|---|---|---|
Market Cap | $29.60B | $34.46B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $75.60 |
52-Week Low | $205.48 | $55.53 |
Enterprise Value | $27.56B | $54.56B |
Dividend Yield | — | 2.56% |
Trailing returns across standard periods
Latest headlines on both assets
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →